Arun Krishnan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1860957/publications.pdf

Version: 2024-02-01

145 papers	5,848 citations	76294 40 h-index	88593 70 g-index
149 all docs	149 docs citations	149 times ranked	5843 citing authors

#	Article	IF	Citations
1	Chemotherapyâ€induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437.	157.7	547
2	Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 2010, 17, 1942-1959.	1.2	225
3	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 2009, 132, 2712-2723.	3.7	198
4	Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle and Nerve, 2005, 32, 51-60.	1.0	194
5	Bell's palsy: aetiology, clinical features and multidisciplinary care. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1356-1361.	0.9	181
6	Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies. Current Medicinal Chemistry, 2008, 15, 3081-3094.	1.2	175
7	Uremic neuropathy: Clinical features and new pathophysiological insights. Muscle and Nerve, 2007, 35, 273-290.	1.0	173
8	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. Oncologist, 2011, 16, 708-716.	1.9	171
9	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. Journal of Clinical Oncology, 2009, 27, 1243-1249.	0.8	153
10	Neurological complications of chronic kidney disease. Nature Reviews Neurology, 2009, 5, 542-551.	4.9	148
11	Axonal ion channels from bench to bedside: A translational neuroscience perspective. Progress in Neurobiology, 2009, 89, 288-313.	2.8	144
12	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	3.7	123
13	Altered nerve excitability properties in established diabetic neuropathy. Brain, 2005, 128, 1178-1187.	3.7	114
14	Neurological complications in chronic kidney disease. JRSM Cardiovascular Disease, 2016, 5, 204800401667768.	0.4	114
15	Altered motor nerve excitability in end-stage kidney disease. Brain, 2005, 128, 2164-2174.	3.7	107
16	Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483.	0.9	93
17	Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain, 2008, 131, 1209-1216.	3.7	87
18	Oxaliplatin and Axonal Na+ Channel Function In vivo. Clinical Cancer Research, 2006, 12, 4481-4484.	3.2	82

#	Article	IF	Citations
19	Nerve function and dysfunction in acute intermittent porphyria. Brain, 2008, 131, 2510-2519.	3.7	75
20	Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer. JAMA Neurology, 2018, 75, 980.	4.5	73
21	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxelâ€induced neuropathy. Muscle and Nerve, 2011, 43, 367-374.	1.0	69
22	Association Between Calcineurin Inhibitor Treatment and Peripheral Nerve Dysfunction in Renal Transplant Recipients. American Journal of Transplantation, 2013, 13, 2426-2432.	2.6	69
23	Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treatment Reviews, 2016, 50, 118-128.	3.4	69
24	The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Research, 2009, 1273, 39-47.	1.1	67
25	Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Neurology, 2011, 68, 862.	4.9	63
26	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	0.7	63
27	Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity. PLoS ONE, 2011, 6, e18469.	1.1	61
28	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493.	1.0	59
29	Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 2008, 13, 7-26.	1.4	57
30	Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain, 2005, 128, 1841-1846.	3.7	54
31	Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1202-1208.	0.9	54
32	Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1569-1577.	2.2	53
33	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175.	0.7	50
34	Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes. Diabetes, 2012, 61, 1592-1598.	0.3	48
35	Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 33-38.	2.3	47
36	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 2014, 125, 179-185.	0.7	46

#	Article	IF	Citations
37	Sensory nerve excitability and neuropathy in end stage kidney disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 548-551.	0.9	45
38	The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis. JAMA Neurology, 2014, 71, 1386.	4.5	45
39	Nerve excitability properties in lower-limb motor axons: Evidence for a length-dependent gradient. Muscle and Nerve, 2004, 29, 645-655.	1.0	43
40	Review: Neuromuscular Disease in the Dialysis Patient: An Update for the Nephrologist. Seminars in Dialysis, 2009, 22, 267-278.	0.7	42
41	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2460-2467.	0.7	42
42	Exploring the Evolution of Cortical Excitability Following Acute Stroke. Neurorehabilitation and Neural Repair, 2016, 30, 244-257.	1.4	40
43	Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clinical Neurophysiology, 2006, 117, 992-999.	0.7	38
44	The Pathophysiology of Oxaliplatin-Induced Neurotoxicity. Current Medicinal Chemistry, 2006, 13, 2901-2907.	1.2	38
45	Sonographic differences in carpal tunnel syndrome with normal and abnormal nerve conduction studies. Journal of Clinical Neuroscience, 2016, 34, 77-80.	0.8	38
46	Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle and Nerve, 2016, 54, 967-969.	1.0	37
47	Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 2013, 27, 219-229.	1.4	35
48	Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 2013, 36, 1272-1277.	4.3	30
49	Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle and Nerve, 2006, 33, 627-636.	1.0	29
50	Mechanisms of axonal dysfunction in diabetic and uraemic neuropathies. Clinical Neurophysiology, 2013, 124, 2079-2090.	0.7	29
51	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 53-59.	1.7	29
52	Sleep-Disordered Breathing in People with Multiple Sclerosis: Prevalence, Pathophysiological Mechanisms, and Disease Consequences. Frontiers in Neurology, 2017, 8, 740.	1.1	28
53	Relationship between corneal confocal microscopy and markers of peripheral nerve structure and function in Type 2 diabetes. Diabetic Medicine, 2020, 37, 326-334.	1.2	28
54	Conduction block and impaired axonal function in tick paralysis. Muscle and Nerve, 2009, 40, 358-362.	1.0	27

#	Article	IF	Citations
55	Tear film substance P: A potential biomarker for diabetic peripheral neuropathy. Ocular Surface, 2019, 17, 690-698.	2.2	27
56	Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain, 2006, 129, 1585-1592.	3.7	26
57	Ischaemic sensitivity of axons in carpal tunnel syndrome. Journal of the Peripheral Nervous System, 2009, 14, 190-200.	1.4	26
58	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 2017, 128, 2022-2028.	0.7	25
59	Correlation between markers of peripheral nerve function and structure in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3028.	1.7	25
60	Segmental Facial Anhidrosis and Tonic Pupils With Preserved Deep Tendon Reflexes: A Novel Autonomic Neuropathy. Journal of Neuro-Ophthalmology, 2005, 25, 5-8.	0.4	24
61	Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow. Muscle and Nerve, 2017, 55, 77-83.	1.0	24
62	Acute transverse myelitis in SLE. Neurology, 2004, 62, 2087-2087.	1.5	23
63	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993.	1.1	23
64	Riche-Cannieu anastomosis as an inherited trait. Clinical Neurophysiology, 2007, 118, 770-775.	0.7	21
65	Axonal excitability properties in hemifacial spasm. Movement Disorders, 2007, 22, 1293-1298.	2.2	21
66	Changes in human sensory axonal excitability induced by an ischaemic insult. Clinical Neurophysiology, 2008, 119, 2054-2063.	0.7	21
67	Oxaliplatin-Induced Lhermitteâ€™s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Oncology, 2009, 77, 342-348.	0.9	21
68	Botulinum toxin modulates cortical maladaptation in postâ€stroke spasticity. Muscle and Nerve, 2013, 48, 93-99.	1.0	21
69	Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 385-391.	1.4	20
70	Conduction block in immuneâ€mediated neuropathy: paranodopathy versus axonopathy. European Journal of Neurology, 2019, 26, 1121-1129.	1.7	19
71	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 2011, 227, 120-127.	2.0	18
72	Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. PLoS ONE, 2013, 8, e59055.	1.1	18

#	Article	IF	Citations
73	Axonal function in a family with episodic ataxia type 2 due to a novel mutation. Journal of Neurology, 2008, 255, 750-755.	1.8	17
74	Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 2010, 126, e734-e739.	1.0	17
75	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. Clinical Neurophysiology, 2016, 127, 1700-1706.	0.7	17
76	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes, 2017, 66, 1661-1670.	0.3	17
77	Hypokalemic weakness in hyperaldosteronism: Activity-dependent conduction block. Neurology, 2005, 65, 1309-1312.	1.5	16
78	Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 2013, 12, 826-834.	1.4	16
79	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218.	1.6	16
80	Focal Ischaemic Infarcts Expand Faster in Cerebellar Cortex than Cerebral Cortex in a Mouse Photothrombotic Stroke Model. Translational Stroke Research, 2018, 9, 643-653.	2.3	16
81	Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease. Nephrology Dialysis Transplantation, 2022, 37, 713-719.	0.4	16
82	Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. Clinical Neurophysiology, 2017, 128, 281-286.	0.7	15
83	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	0.7	15
84	Potassium control in chronic kidney disease: implications for neuromuscular function. Internal Medicine Journal, 2019, 49, 817-825.	0.5	15
85	A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy. Translational Vision Science and Technology, 2021, 10, 24.	1.1	15
86	Porphyric neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 613-627.	1.0	14
87	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2014, 49, 858-865.	1.0	14
88	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	2.0	14
89	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2015, 31, 175-182.	1.7	14
90	Central sleep apnea in multiple sclerosis: a pilot study. Sleep and Breathing, 2017, 21, 691-696.	0.9	14

#	Article	IF	Citations
91	The utility of the Total Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease: A validation study. Clinical Neurophysiology, 2018, 129, 889-894.	0.7	14
92	The Effect of Age, Gender and Body Mass Index on Tear Film Neuromediators and Corneal Nerves. Current Eye Research, 2020, 45, 411-418.	0.7	14
93	A Comparative Study on the Diagnostic Utility of Corneal Confocal Microscopy and Tear Neuromediator Levels in Diabetic Peripheral Neuropathy. Current Eye Research, 2020, 45, 921-930.	0.7	14
94	Excitability differences in lower-limb motor axons during and after ischemia. Muscle and Nerve, 2005, 31, 205-213.	1.0	13
95	Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. Clinical Neurophysiology, 2019, 130, 2088-2095.	0.7	13
96	Corneal nerve fiber loss in diabetes with chronic kidney disease. Ocular Surface, 2020, 18, 178-185.	2.2	13
97	The impact of anticancer drugs on the ocular surface. Ocular Surface, 2020, 18, 403-417.	2.2	13
98	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathyâ€”a randomised controlled trial. Supportive Care in Cancer, 2021, 29, 1103-1110.	1.0	12
99	Impact of the metabolic syndrome on peripheral nerve structure and function in type 2 diabetes. European Journal of Neurology, 2021, 28, 2074-2082.	1.7	12
100	Tear film and ocular surface neuropeptides: Characteristics, synthesis, signaling and implications for ocular surface and systemic diseases. Experimental Eye Research, 2022, 218, 108973.	1.2	12
101	Association of corneal nerve loss with markers of axonal ion channel dysfunction in type 1 diabetes. Clinical Neurophysiology, 2020, 131, 145-154.	0.7	11
102	Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis. Current Medicinal Chemistry, 2015, 22, 4366-4378.	1.2	11
103	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. Scientific Reports, 2021, 11, 22884.	1.6	11
104	Activity-induced weakness in recessive myotonia congenita with a novel (696+1G>A) mutation. Clinical Neurophysiology, 2006, 117, 2064-2068.	0.7	10
105	Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2636-2642.	0.7	10
106	Nerve excitability in the rat forelimb: a technique to improve translational utility. Journal of Neuroscience Methods, 2017, 275, 19-24.	1.3	10
107	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. Clinical Neurophysiology, 2017, 128, 93-99.	0.7	10
108	Sonographic assessment of nerve blood flow in diabetic neuropathy. Diabetic Medicine, 2020, 37, 343-349.	1.2	10

#	Article	IF	Citations
109	Evidence of Altered Peripheral Nerve Function in a Rodent Model of Diet-Induced Prediabetes. Biomedicines, 2020, 8, 313.	1.4	10
110	Associations between acute glucose control and peripheral nerve structure and function in type 1 diabetes. Diabetic Medicine, 2020, 37, 1553-1560.	1.2	10
111	A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. Scientific Reports, 2021, 11, 1786.	1.6	10
112	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1365-1375.	2.2	10
113	Transynaptic Changes Evident in Peripheral Axonal Function After Acute Cerebellar Infarct. Cerebellum, 2014, 13, 669-676.	1.4	9
114	The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo. PLoS ONE, 2016, 11, e0153389.	1.1	9
115	Effects of hemodialysis on intraneural blood flow in endâ€stage kidney disease. Muscle and Nerve, 2018, 57, 287-293.	1.0	9
116	Intracranial and dermatological cryptococcal infection in an immunocompetent man. Journal of Clinical Neuroscience, 2004, 11, 765-767.	0.8	8
117	Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment?. Journal of Clinical Oncology, 2011, 29, e553-e554.	0.8	8
118	Impaired energyâ€dependent processes underlie acute lead neuropathy. Muscle and Nerve, 2012, 46, 954-956.	1.0	8
119	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. BMJ Open, 2019, 9, e023736.	0.8	8
120	Effect of exenatide on peripheral nerve excitability in type 2 diabetes. Clinical Neurophysiology, 2021, 132, 2532-2539.	0.7	8
121	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 2011, 122, 194-198.	0.7	7
122	The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 2011, 44, 841-841.	1.0	7
123	Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. Muscle and Nerve, 2016, 54, 58-64.	1.0	7
124	Corneal nerve changes following treatment with neurotoxic anticancer drugs. Ocular Surface, 2021, 21, 221-237.	2.2	7
125	Disorders of vision in multiple sclerosis. Australasian journal of optometry, The, 2022, 105, 3-12.	0.6	7
126	Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes. Muscle and Nerve, 2022, 65, 603-607.	1.0	7

#	Article	IF	Citations
127	The provision of written information and its effect on levels of pain and anxiety during electrodiagnostic studies: A randomised controlled trial. PLoS ONE, 2018, 13, e0196917.	1.1	6
128	Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. Clinical Neurophysiology, 2020, 131, 783-790.	0.7	5
129	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
130	Cytoplasmic body myopathy masquerading as motor neuron disease. Muscle and Nerve, 2004, 30, 667-672.	1.0	4
131	Assessment of axonal excitability properties in two branches of the human facial nerve. Journal of Neuroscience Methods, 2016, 274, 53-60.	1.3	4
132	Motor unit number estimation of facial muscles using the M Scanâ€Fit method. Muscle and Nerve, 2020, 62, 555-558.	1.0	3
133	Automated analysis of corneal nerve tortuosity in diabetes: implications for neuropathy detection. Australasian journal of optometry, The, 2022, 105, 487-493.	0.6	3
134	Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders. Pharmaceuticals, 2022, 15, 607.	1.7	3
135	Another Cause of Occupational Entrapment Neuropathy: La Main Du Cuisinier (The Chefâ€™s Hand). Journal of Clinical Neurophysiology, 2009, 26, 129-131.	0.9	2
136	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. Cancer Chemotherapy and Pharmacology, 2011, 67, 1189-1190.	1.1	2
137	Chemotherapy-induced peripheral neuropathy: the end of the beginning?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 359-359.	0.9	2
138	In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing. Journal of Visualized Experiments, 2018, , .	0.2	2
139	Altered axonal excitability properties in facial palsy. Muscle and Nerve, 2018, 57, 268-272.	1.0	2
140	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 2018, 57, 615-621.	1.0	2
141	Altered peripheral nerve structure and function in latent autoimmune diabetes in adults. Diabetes/Metabolism Research and Reviews, 2020, 36, e3260.	1.7	2
142	CKD 5D epidemiology and outcomes. Nephrology Dialysis Transplantation, 2012, 27, ii70-ii72.	0.4	1
143	Ion channel dysfunction and peripheral nerve hyperexcitability. Clinical Neurophysiology, 2015, 126, 1069-1070.	0.7	1
144	The Impact of Post-Tear Collection Storage on Tear Film Substance P Concentration. Current Eye Research, 2022, 47, 1116-1120.	0.7	1

#	Article	IF	Citations
145	Polyneuropathy in POEMS syndrome: Alterations in nerve function and morphology. Clinical Neurophysiology, 2015, 126, 1845-1846.	0.7	0